FDA Cites Manufacturing Concerns At Wockhardt's U.S. Unit

The U.S. Food and Drug Administration has expressed concerns over production processes at the U.S. unit of Wockhardt Ltd, a top executive said, possibly adding to a spate of regulatory troubles facing the Indian generic drugmaker. The United States is Wockhardt's biggest market and the FDA has already banned the import of generic drugs from its two plants in India , citing quality lapses in the manufacturing process. Managing Director Murtaza Khorakiwala said on Tuesday Wockhardt had responded to the FDA's observations but declined to give details.

Help employers find you! Check out all the jobs and post your resume.